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Abstract 
Background: The apolipoprotein (APOE) e4 locus is a genetic risk factor for dementia. Carriers 
of the e4 allele may be more vulnerable to conditions that are independent risk factors for 
cognitive decline, such as cardiometabolic diseases.  
Objective: We tested whether any association with APOE e4 status on cognitive ability was 
larger in older ages, or in those with cardiometabolic diseases.  
Subjects: UK Biobank includes over 500,000 middle- and older-aged adults who have undergone 
detailed medical and cognitive phenotypic assessment. Around 150,000 currently have genetic 
data. We examined 111,739 participants with complete genetic and cognitive data.  
Methods: Baseline cognitive data relating to information processing speed, memory and 
reasoning were used. We tested for interactions with age and with presence vs. absence of type-2 
diabetes (T2D), coronary artery disease (CAD) and hypertension.  
Results: In several instances APOE e4 dosage interacted with older age and disease presence to 
affect cognitive scores. When adjusted for potentially confounding variables there was no APOE 
e4 effect on the outcome variables.  
Conclusions: Future research in large independent cohorts should continue to investigate this 
important question, which has potential implications for aetiology related to dementia and 
cognitive impairment.  
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Highlights 
• It is of great public health interest to determine if genetic and environmental risk factors for 
dementia interact.  
• Effects of APOE e4 genotype on cognitive ability may be stronger in older ages, or in people 
with cardiometabolic diseases. 
• Large sample size, homogenous ancestry and cognitive data in UK Biobank make the cohort 
very valuable.  
• We tested our hypothesis in around 112,000 UK Biobank participants with genetic, cognitive 
and sociodemographic data.  
• We found no evidence that older age or cardiometabolic diseases modified association 
between APOE e4 and cognitive ability. 
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Introduction 
Alzheimer disease (AD) is a type of progressive dementia characterized by cognitive impairment, 
and genetic variation in the apolipoprotein e (APOE) region is a risk factor. Previous studies have 
reported worse cognitive abilities in non-demented people with the APOE e4 allele (e3/e4, e4/e4 
and occasionally e2/e4 genotypes), compared with those with the e2/e2, e2/e3 or e3/e3 genotype. 
Wisdom et al. reported a meta-analysis including 40,942 participants with a mean age of 63.14 
years (standard deviation [SD] = 13.10). Significant negative associations were found between 
presence of the e4 allele and cognitive abilities relating to memory, global cognitive function, 
executive function and information processing speed, but not verbal ability, primary memory, 
attention or visuospatial functions1.  
A recent paper using the CHARGE consortium data2, which includes 543,949 European 
participants from 31 cohorts, all aged over 45 years and without dementia, identified 13 single 
nucleotide polymorphisms (SNPs) that were significantly associated with fluid cognitive function 
as derived from several diverse cognitive tests. The magnitude of the association between 
rs10119 in the APOE region, and worse cognitive ability, increased with the mean age of each 
cohort (r = -0.42, P = 0.022).  The effect was close to zero in younger cohorts, aged around 55-60 
years, and most pronounced in the oldest cohorts, aged around 80 years2. A report using the 
Generation Scotland cohort (N = 18,337) reported effects of APOE e4 dosage (0 vs. 1 vs. 2) on 
Logical Memory (standardised beta = -0.095P = 0.003), Verbal Fluency (standardised beta = 
0.075, P = 0.023), and Digit Symbol tests (standardised beta = -0.087, P = 0.004), only in 
participants aged over 60 years3. In summary, there is evidence from relatively large cross-
sectional studies that the effect of e4 genotype may become stronger in older ages4,5.  
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The APOE locus has been referred to as the ‘frailty gene’6,7, because it is associated with 
increased risk of diseases which lead to disability8, and e4 carriers are perhaps less likely to 
recover well9. Recent studies have investigated possible interactions between the e4 allele and 
cardiometabolic diseases.  Perna et al. reported that in the ESTHER and KAROLA cohorts (total 
N = 1800), the negative association between APOE e4 presence and performance on the 
Cognitive Telephone Screening Instrument (COGTEL) was significantly stronger in participants 
with hypercholesterolemia (interaction P-values <0.05). There is a lack of high quality data on 
the possible interactive effect of APOE e4 genotype and cardiometabolic risk factors on cognitive 
abilities10.  
UK Biobank is a very large, general population cohort study of 502,649 people from the 
UK, which includes sociodemographic, medical, cognitive and genetic data11.The genetic data are 
to be made available in batches. Genetic data for the first 150,000 participants have been released 
so far. UK Biobank has cognitive data pertinent to a number of domains previously associated 
with APOE e4: episodic memory, executive function and processing speed1. This study aimed to 
ascertain whether APOE e4 allele dosage was associated with cognitive function in a large, 
single-cohort population sample, represented by the currently released UK Biobank genotype 
dataset; whether genotype effects are stronger in older ages, or interact with cardiometabolic 
disease.  
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Methods 
Materials and procedure 
The UK Biobank baseline assessment took place between 2006 and 2010 in one of 22 assessment 
centres.  In total 502,649 participants were recruited, aged 40-70 years, and from the general 
population. Invitation letters were sent to eligible adults registered with the NHS and living 
within 25 miles of a study assessment centre. Participants completed a touchscreen questionnaire 
related to various topics including sociodemographic, physical and mental health, early life 
factors, and a relatively brief battery of cognitive tests.  
This study focuses on three cognitive tests that were included in UK Biobank, each 
administered via computerised touchscreen interface. The first of these was a task with thirteen 
logic/reasoning-type questions and a two-minute time limit, labelled as ‘fluid intelligence’ in the 
UK Biobank protocol but hereafter referred to as ‘verbal-numerical reasoning’; 
http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=20016). The maximum score is 13. The next task 
was a visual memory test labelled ‘pairs-matching’ 
(http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100030), where participants were asked to 
memorize the positions of six card pairs, and then match them from memory while making as few 
errors as possible. Scores on the pairs-matching test are for the number of errors that each 
participant made; therefore, higher scores reflect poorer cognitive function. We refer to this test 
as the memory task from here on. Finally, participants completed a timed test of symbol 
matching, similar to the common card game ‘Snap’ hereafter referred to as reaction time (RT) 
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=20023). The reasoning task was only added to 
the participant assessment part-way through the baseline assessment phase. Therefore, the sample 
sizes for the different tasks vary. UK Biobank cognitive data have been described previously12. 
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 Participants were asked during the baseline assessment about any previous or current 
cardiometabolic conditions that had been diagnosed by their doctor. Specifically, participants 
were asked whether their doctor had diagnosed myocardial infarction, angina, stroke, 
hypertension or type II diabetes (T2D). We defined coronary artery disease (CAD) as either 
myocardial infarction or angina. We excluded participants who stated only ‘prefer not to answer’. 
Townsend deprivation indices were derived from postcode of residence13. They provide an area-
based measure of socioeconomic deprivation derived from aggregated data on car ownership, 
household overcrowding, owner-occupation and unemployment. Higher Townsend scores equate 
to higher levels of area-based socioeconomic deprivation.  
 
Genotyping 
UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom array for 
~50,000 participants, and the remaining ~450,000 (for the purposes of this study 100,000) on the 
Affymetrix UK Biobank Axiom array. The two are extremely similar. All genetic data were 
quality controlled and imputed by UK Biobank. The APOE e genotype is directly genotyped. 
Further information on the genotyping process is available 
(http://www.ukbiobank.ac.uk/scientists-3/genetic-data), including detailed technical 
documentation (http://www.ukbiobank.ac.uk/wp-
content/uploads/2014/04/UKBiobank_genotyping_QC_documentation-web.pdf). UK Biobank 
provides recommendations, which we followed, for which participants to exclude from analysis, 
generally because the sample failed QC, had significant missing data or heterozygosity. UK 
Biobank also provides 15 separate principal components (PCs) to be included as possible 
covariates in order to limit confounding by population stratification.  
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Statistical analyses 
We included only participants of Caucasian ethnicity, who accounted for the vast majority 
(~95%) of UK Biobank participants. In common with previous studies on APOE e1, we excluded 
participants with the e2/e4 genotype as they have a combination of potentially protective and risk 
alleles.  
Because the RT scores were significantly positively distributed we transformed the 
variable with a natural log transform (‘LN’). The memory error scores were significantly zero-
value inflated and therefore transformed with an LN +1 equation. We ran the models coding 
e2/e2, e2/e3 and e3/e3, e3/e4, and e4/e4 as 0, 1 and 2 respectively, i.e. an e4 dosage model. We 
found no evidence that the results were meaningfully different when we analysed the data as a 
binary APOE e4 present vs. absent model, so simply report the dose effect.  
Participants with zero, one or two APOE e4 alleles were compared on descriptive 
variables with Ç2 tests for trend for ordinal data, using the “nptrend” function in STATA 14. The 
association between APOE e4 dosage and the cognitive function test results was tested using 
linear regression. For log RT and log memory scores we report exponentiated betas where effects 
are multiplicative so that an effect size of 1.00 represents no change, and e.g. beta = 1.01 equates 
to a 1% increase in raw RT scores. For reasoning scores we report unstandardized betas. We 
included 10 genetic PCs, as provided by UK Biobank. We tested whether there were significant 
interactions between APOE, age, and diseases of CAD, T2D and hypertension, and also age in 
years.  
We first ran a base model adjusted for stratification with 10 PCs, and then adjusted for the 
covariates of age and sex (‘partially adjusted model’), and finally self-reported depression, 
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Townsend deprivation index, T2D, CAD and hypertension (‘fully adjusted model’). We tested 
each interaction term in a separate model. Genotype measurement batch, assessment centre and 
type of array made no difference to the final results when included as a covariate and we 
therefore present results without this in the model. As an additional analysis we split the sample 
into those over vs. under 60 years of age, and tested for an effect of APOE e4 at first unadjusted, 
and then adjusted for stratification and sex. This method of analysis is similar to that reported by 
Marioni et al. Because of the large sample size and partly to offset the risk of multiple 
comparisons we elected to use P <0.001 as nominal significance. Age was centred on 60 years. 
All analyses were conducted using IBM SPSS v.22 unless otherwise stated.   
 
Results 
 [Insert Table 1 here] 
  
Of 152,248 UK Biobank participants who had APOE genotyping, we first excluded participants 
that either reported a brain disease that may affect cognitive ability directly (see Appendix 1 in 
supplementary data) or did not provide that information: this left 145,278 participants. We 
excluded non-Caucasian participants, leaving n = 130,381. We removed participants who had a 
relatedness coefficient above 0.0442 (n = 15,625), or mismatch between reported and genetic sex 
(n = 152), leaving N = 114,604. We then removed participants who failed UK Biobank or BiLeve 
quality controlling (QC; n = 281), leaving N = 114,323 One participant was removed because 
they were aged over 70 years (above the official upper baseline age limit). This left a total of 
114,322 participants with APOE data. Of those, 1,087 (1.0%) had APOE genotype e2/e2; 13,352 
(11.7%) had e2/e3; 2,583 (2.3%) had e2/e4; 72,001 (63.0%) had e3/e3; 22,029 (19.3%) had e3/e4 
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and 3,270 (2.9%) had e4/e4. The allele frequencies were: e2 = 7.92%, e3 = 78.46% and e4 = 
13.62%. The APOE e genotype was in Hardy-Weinberg equilibrium (P = 0.08). Because we 
excluded the e2/e4 carriers from analysis, the final sample was 111,739. The mean age was 56.79 
years (SD = 7.94), and 52,679 (47.1%) were male. Frequencies of diseases and demographics by 
genotype are shown in Table 1. Of the 111,739 participants, 36,135 had reasoning data, 111,651 
pairs-matching data, and 111,137 RT data. 
 
[Insert Table 2 here] 
 
Reasoning scores 
In the base model, partially adjusted and fully adjusted models there was no association between 
APOE e4 dosage and reasoning scores (Table 2). In the base model there was a significant 
interaction between APOE e4 and CAD, and between APOE e4 and age, but no associations 
remained significant in the fully adjusted model.  
 
Reaction time 
In the base model there were several significant interactions (i.e. P value <0.001) between APOE 
e4 and cardiometabolic diseases, and age (Table 2). Most of these interactions attenuated in the 
partially adjusted model however, and none were significant in the fully adjusted model.  
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Pairs matching (memory) error scores 
In the base model there were significant interactions between APOE e4 dosage and hypertension, 
and age, on log memory errors. However there were no significant interactions in the partially or 
fully adjusted models (Table 2).  
 
Age-stratified analyses 
When we split the sample into participants aged over vs. under 60 years, there was no evidence of 
a significant APOE e4 effect (at P = 0.001) in either group whether unadjusted, or corrected for 
stratification (with 10 PCs) and sex (Appendix 2).  
 
Discussion 
Interpretation 
In our study of around 112,000 participants of UK Biobank we found some statistically 
significant interactions between APOE e4 dosage and age/disease variables: for reasoning scores 
with CAD and age; for RT scores with CAD, T2D, hypertension and age, and for pairs matching 
memory errors with hypertension and age. However none of these interactions were significant in 
the fully adjusted model. 
Our findings partly contrast with the recent finding by Davies et al. who reported that the 
e4 effect on fluid mental ability was much more pronounced in older age2. Specifically, Davies et 
al. noted that the APOE e4 effect size was mostly apparent at ages above 60 years, increasing 
relatively linearly until around age 80 (the mean age of the oldest cohort). Marioni et al. found 
generally weaker associations in participants aged under 60 years; in contrast we found no 
significant associations with APOE e4 dosage when we stratified participants in this way. We 
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found no interactions with self-reported T2D, hypertension or CAD for any of the cognitive tests 
in fully adjusted analyses. This is in contrast to a recent studies which showed significant 
interaction between APOE e4 and presence of cardiometabolic disease on cognitive function10,15.  
Wisdom et al. reported on 77 studies including 40,942 participants with APOE and 
cognitive data, and reported generally small effects (r coefficients ranged from -0.07 for episodic 
memory, to -0.002 for verbal ability), which are mostly larger than seen here. (We recommend 
the Wisdom et al. report for collating a large number of individual studies, detailed therein, 
although several reports of APOE  e4 genotype and non-pathological cognitive ability in older 
adults been published since, generally showing significant associations with small-to-medium 
effect sizes 3,10,16–21). Our study is based on a single very large cohort where participants 
completed the same battery of cognitive function tests. In contrast, the report by Wisdom et al. 
pooled effect sizes from different studies using different measures (although the authors were 
careful to include only validated tests). Our results also statistically control for a number of 
factors – e.g. deprivation – that Wisdom et al. did not. Therefore, it is possible that our largely 
negative findings are a more accurate reflection of the impact of APOE e4 on the cognitive 
function of people in middle age or early old age who are not affected by dementia. However, 
these unexpected findings require significant validation and replication in future studies, 
particularly when the UK Biobank genetic data are available on the full cohort of 502,649 
participants. It is common for effect sizes in single-locus association studies to weaken when 
more participants are added 22,23. It should also be noted that UK Biobank did not assess any tasks 
related to verbal episodic memory, which is the domain which Wisdom et al. reported had the 
strongest association with APOE e4 genotype.  
Our study was cross-sectional and did not consider the effects of APOE e4 on longitudinal 
cognitive change24. Future research will address this. In addition, since the baseline assessment, 
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UK Biobank has assessed participants on cognitive tests based on well-validated tasks such as 
Trail Making Test, and Tower of Hanoi, and we will investigate these also.   
 
Limitations 
UK Biobank are unlikely to be perfectly representative of the general population in terms of age, 
sex, ethnicity and socioeconomic status within the age-range recruited 25. However, in common 
with other general population cohorts, it is likely to be unrepresentative in other aspects. People 
with very low cognitive ability may have been less likely to participate due to various reasons 
including but not limited to inability to provide informed consent, or difficulties in participating. 
Also, since recruitment occurred in middle and old age, survival bias may have been introduced. 
If the range of cognitive ability among participants was reduced as a result, this may have masked 
a true association between genotype and cognitive ability.  
 It is also possible that the UK Biobank cognitive tests are insensitive, which may mask or 
partly offset the deleterious effects of APOE e4 genotype on mental function. Due to the very 
large scale of UK Biobank, the cognitive battery had to be delivered within a very short time-
window. The tests also needed to be self-completed via a touch-screen computer. Therefore, they 
were relatively novel although based in principal on existing cognitive tasks. It is possible that 
some participants, uncomfortable with what could be considered a ‘high tech’ computerized 
approach, may have declined to participant, and this could theoretically have introduced some 
bias although it should be noted that only a very small minority of participants refuse to complete 
the cognitive assessment. The tests used here have shown a main effect of age12, implying they 
are at least relatively sensitive metrics of cognitive change.  
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Conclusions 
The APOE e4 locus has been significantly associated with cognitive ability in non-demented 
adults, and there is prior evidence that the effect may increase with age, and perhaps modify the 
negative association with cardiometabolic diseases. We tested for these effects in 111,739 UK 
Biobank participants. We found significant interactions between APOE e4 genotype with 
presence of cardiometabolic diseases, and older age on cognitive abilities, although the effects 
were small and did not survive correction for confounders. Given the large sample sizes reported 
here, it is also possible that the unadjusted significant findings reflect type-1 error. Future studies 
should continue to investigate whether genetic risk factors for lower mental ability have a greater 
effect into older age, including when more genetic and cognitive data is available in UK Biobank.  
 
Table contents 
Table 1: Clinical and demographic characteristics 
Table 2: Associations between APOE e4 dosage, cardiometabolic diseases and cognitive scores 
Appendix 1: Excluded (self-reported) diseases 
Appendix 2: APOE e4 and cognitive abilities in people stratified by under vs. over 60 years of 
age 
 
References 
1  Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired 
cognitive functioning: a meta-analysis. Neurobiol Aging 2011; 32: 63–74. 
2  Davies G, Armstrong N, Bis JC, Bressler J, Chouraki V, Giddaluru S, et al. Genetic 
contributions to variation in general cognitive function: a meta-analysis of genome-wide 
16 
 
association studies in the CHARGE consortium (N=53949). Mol Psychiatry 2015; 20: 
183–92. 
3  Marioni RE, Campbell A, Scotland G, Hayward C, Porteous DJ, Deary IJ. Differential 
effects of the APOE e4 allele on different domains of cognitive ability across the life-
course. Eur J Hum Genet 2015. doi:10.1038/ejhg.2015.210. 
4  Papenberg G, Lindenberger U, Bäckman L. Aging-related magnification of genetic effects 
on cognitive and brain integrity. Trends Cogn Sci 2015. doi:10.1016/j.tics.2015.06.008. 
5  Laukka EJ, Lövdén M, Herlitz A, Karlsson S, Ferencz B, Pantzar A, et al. Genetic effects 
on old-age cognitive functioning: a population-based study. Psychol Aging 2013; 28: 262–
74. 
6  Smith JD. Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev 2002; 1: 
345–65. 
7  Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, et al. Apolipoprotein 
e gene variability and cognitive functions at age 79: a follow-up of the Scottish mental 
survey of 1932. Psychol Aging 2004; 19: 367–71. 
8  McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic 
cerebrovascular disease: A meta-analysis. Neurology 1999; 53: 1308–1308. 
9  Zhou W, Xu D, Peng X, Zhang Q, Jia J, Crutcher KA. Meta-Analysis of APOE 4 Allele 
and Outcome after Traumatic Brain Injury. J Neurotrauma 2008; 25: 279–90. 
10  Bangen KJ, Beiser A, Delano-Wood L, Nation DA, Lamar M, Libon DJ, et al. APOE 
Genotype Modifies the Relationship between Midlife Vascular Risk Factors and Later 
Cognitive Decline. J Stroke Cerebrovasc Dis 2013; 22: 1361–9. 
17 
 
11  Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An 
Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases 
of Middle and Old Age. PLoS Med 2015; 12: e1001779. 
12  Cullen B, Nicholl BI, Mackay DF, Martin D, Ul-Haq Z, McIntosh A, et al. Cognitive 
function and lifetime features of depression and bipolar disorder in a large population 
sample: Cross-sectional study of 143,828 UK Biobank participants. Eur Psychiatry 2015; 
30: 950–8. 
13  Townsend P. Townsend deprivation index. Natl. database Prim. care groups Trust. 1998. 
14  StataCorp. Stata Statistical Software: Release 11. Econ. J. 2009; 102. 
doi:10.2307/2234838. 
15  Perna L, Mons U, Rujescu D, Kliegel M, Brenner H. Apolipoprotein E e4 and Cognitive 
Function: A Modifiable Association? Results from Two Independent Cohort Studies. 
Dement Geriatr Cogn Disord 2015; 41: 35–45. 
16  Davies G, Harris SE, Reynolds C a, Payton  a, Knight HM, Liewald DC, et al. A genome-
wide association study implicates the APOE locus in nonpathological cognitive ageing. 
Mol Psychiatry 2014; 19: 76–87. 
17  Gerritsen L, Comijs HC, Deeg DJH, Penninx BWJH, Geerlings MI. Salivary cortisol, 
APOE-µ4 allele and cognitive decline in a prospective study of older persons. Neurobiol 
Aging 2011; 32: 1615–25. 
18  Izaks GJ, Gansevoort RT, van der Knaap AM, Navis G, Dullaart RPF, Slaets JPJ. The 
association of APOE genotype with cognitive function in persons aged 35 years or older. 
PLoS One 2011; 6: e27415. 
18 
 
19  Woodfield R, Grant I, Sudlow CLM. Accuracy of Electronic Health Record Data for 
Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review 
from the UK Biobank Stroke Outcomes Group. PLoS One 2015; 10: e0140533. 
20  Caselli RJ, Dueck AC, Locke DEC, Hoffman-Snyder CR, Woodruff BK, Rapcsak SZ, et 
al. Longitudinal modeling of frontal cognition in APOE µ4 homozygotes, heterozygotes, 
and noncarriers. Neurology 2011; 76: 1383–8. 
21  Lyall DM, Harris SE, Bastin ME, Muñoz Maniega S, Murray C, Lutz MW, et al. Are 
APOE [ genotype and TOMM40 poly-T repeat length associations with cognitive ageing 
mediated by brain white matter tract integrity? Transl Psychiatry 2014; 4: e449. 
22  Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, et al. 
Confidence and precision increase with high statistical power. Nat Rev Neurosci 2013; 14: 
585–6. 
23  Lyall DM, Lopez LM, Bastin ME, Maniega SM, Penke L, Valdés Hernández M del C, et 
al. ADRB2, brain white matter integrity and cognitive ageing in the Lothian Birth Cohort 
1936. Behav Genet 2013; 43: 13–23. 
24  Schiepers OJG, Harris SE, Gow AJ, Pattie A, Brett CE, Starr JM, et al. APOE E4 status 
predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the 
Lothian Birth Cohort 1921. Mol Psychiatry 2011; 17: 315–24. 
25  Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and 
characteristics of probable major depression and bipolar disorder within UK Biobank: 
Cross-sectional study of 172,751 participants. PLoS One 2013; 8. 
doi:10.1371/journal.pone.0075362. 
19 
 
Table 1: Clinical and demographic characteristics 
P-values (two-tailed) for frequency statistics (e.g. depression) are based on Ç2 trend tests for 
continuous/categorical data. RT = reaction time, IQR = interquartile range, SD = standard 
deviation. 
 APOE e2/e2, e2/e3 and 
e3/e3 (N = 86,440)  
APOE e3/e4  
(N = 22,029)  
APOE e4/e4  
(N = 3,270) 
P value 
Age, mean (SD) 56.85 (7.94) 56.59 (7.95) 56.53 (7.89) <0.001 
Sex, male N (%) 40,773 (47.2) 10,307 (46.8) 1,599 (48.9) 0.663 
Townsend deprivation score,  
mean (SD) 
-1.48 (2.99) -1.57 (2.94) -1.47 (3.07) 0.002 
Reasoning scores, mean (SD) 6.16 (2.10) 6.23 (2.10) 6.13 (2.14) 0.130 
Log transformed RT score,  
mean (SD) 
6.30 (0.18) 6.30 (0.18) 6.29 (0.18) 0.262 
Untransformed RT score,   
median (IQR) 
535 (477-605) 535 (477-605) 531 (476-602) 0.262 
Log-transformed pairs-matching 
errors, mean (SD) 
1.43 (0.64) 1.43 (0.64) 1.44 (0.65) 0.273 
Untransformed pairs-matching 
errors, median (IQR)  
3 (2-5) 3 (2-5) 3 (2-6) 0.273 
     
Depression, N (%) 4,926 (5.7) 1,345 (6.1) 177 (5.4) 0.195 
Hypertension, N (%) 23,333 (27.0) 5,905 (26.8) 849 (26.0) 0.226 
Type-2 diabetes, N (%) 4,527 (5.2) 990 (4.5) 139 (4.3) <0.001 
Coronary artery disease, N (%) 3,838 (4.4) 1,074 (4.9) 157 (4.8) 0.008 
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Table 2: Associations between APOE e4 dosage, cardiometabolic diseases and cognitive scores 
  
CI confidence interval; CAD coronary artery disease; T2D type II diabetes 
1adjusted for stratification (with ten principal components).  
2adjusted for stratification, age and sex.  
3additionally stratification, age, sex, depression, Townsend scores, T2D, hypertension and CAD. 
*exponentiated beta coefficients.  
  
Base model1 
Partially adjusted2  
Fully adjusted3 
 Beta 
coefficient 
95% CI 
 
P-value Beta 
coefficient 
95% CI 
 
P-value Beta 
coefficient 
95% CI 
 
P-value 
 Fluid reasoning 
 
APOE e4 (dosage) 0.031 -0.013 0.076 0.161 0.029 -0.015 0.072 0.202 0.031 -0.013 0.074 0.164 
APOE e4 x  CAD -0.378 -0.554 -0.202 <0.001 -0.335 -0.511 -0.159 <0.001 0.080 -0.117 0.277 0.425 
APOE e4 x  type-2 diabetes -0.129 -0.308 0.049 0.155 -0.107 -0.285 0.071 0.238 0.046 -0.149 0.241 0.643 
APOE e4 x  hypertension -0.085 -0.163 -0.007 0.034 -0.045 -0.123 0.033 0.259 0.077 -0.007 0.161 0.073 
APOE e4 x  age -0.018 -0.023 -0.013 <0.001 -0.002 -0.008 0.003 0.367 -0.002 -0.008 0.003 0.356 
  
Log reaction time* 
APOE e4 (dosage) 0.999 0.996 1.001 0.197 1.000 0.998 1.002 0.806 1.001 0.998 1.003 0.605 
APOE e4 x  CAD 1.033 1.024 1.042 <0.001 1.008 1.000 1.017 0.048 0.994 0.985 1.004 0.232 
APOE e4 x  type-2 diabetes 1.030 1.021 1.040 <0.001 1.016 1.007 1.025 <0.001 1.004 0.994 1.013 0.452 
APOE e4 x  hypertension 1.019 1.015 1.023 <0.001 1.004 1.000 1.008 0.032 0.999 0.995 1.003 0.739 
APOE e4 x  age 1.005 1.005 1.005 <0.001 1.000 1.000 1.000 0.138 1.000 1.000 1.000 0.092 
  
Log memory errors* 
APOE e4 (dosage) 1.004 0.997 1.012 0.278 1.007 0.999 1.014 0.074 1.007 0.999 1.014 0.078 
APOE e4 x  CAD 1.034 1.003 1.067 0.030 0.989 0.959 1.020 0.478 0.993 0.960 1.028 0.701 
APOE e4 x  type-2 diabetes 0.990 0.959 1.023 0.555 0.965 0.935 0.996 0.029 0.980 0.947 1.015 0.269 
APOE e4 x  hypertension 1.035 1.021 1.049 <0.001 1.010 0.997 1.024 0.144 1.005 0.991 1.020 0.494 
APOE e4 x  age 1.008 1.007 1.009 <0.001 1.000 0.999 1.000 0.398 1.000 0.999 1.000 0.403 
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Appendix 1: Excluded (self-reported) diseases  
Brain cancer/primary malignant tumour 
Brain haemorrhage 
Brain/intracranial abscess 
Cerebral aneurysm 
Cerebral palsy 
Chronic/degenerative neurological problem 
Dementia/Alzheimer disease/cognitive impairment 
Encephalitis 
Epilepsy  
Head injury 
Infection of nervous system 
Ischaemic stroke 
Meningeal cancer/malignant meningioma 
Meningioma (benign) 
Meningitis 
Motor neurone disease 
Multiple sclerosis 
Neurological injury/trauma 
Neuroma (benign) 
Other demyelinating condition 
Other neurological problem 
Parkinson disease 
Spina bifida 
Stroke 
Subarachnoid haemorrhage 
Subdural haematoma 
Transient ischaemic attack
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Appendix 2: APOE e4 and cognitive abilities in people stratified by under vs. over 60 years of age 
CI confidence interval; CAD coronary artery disease; T2D type II diabetes.  
*exponentiated.   
 
 
 Under 60 years 
 
 Fluid reasoning (N = 19,252) Log reaction time (N = 61,969) Log memory errors (N = 62,145) 
 Beta 
coefficient 
95% CI 
 
P-value Beta 
coefficient* 
95% CI 
 
P-value Beta 
coefficient* 
95% CI 
 
P-value 
APOE e4 (dosage)             
Unadjusted 0.061 0.001 0.122 0.047 1.002 0.999 1.005 0.121 1.007 0.997 1.017 0.153 
Adjusted for sex and 
stratification 
 
0.058 -0.003 0.118 0.061 1.002 0.999 1.005 0.142 1.007 0.998 1.017 0.140 
  
Over 60 years 
 
 Fluid reasoning (N = 16,883) Log reaction time (N = 49,168) Log memory errors (N = 49,506) 
APOE e4 (dosage)             
Unadjusted -0.011 -0.075 0.053 0.733 0.997 0.993 1.000 0.043 1.004 0.992 1.016 0.498 
Adjusted for sex and 
stratification 
-0.006 -0.070 0.057 0.884 0.997 0.994 1.000 0.056 1.004 0.993 1.016 0.469 
